{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-038030","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.409270+00:00","generated_at":"2026-06-08T06:39:52.229338+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Avalo eliminates $35M debt, Q3 net loss $5.2M; cash $10.2M; divests 800 series for up to $45M","bullets":["Paid off remaining $14.3M of $35M debt to Horizon Technology; all loan obligations satisfied.","Divested AVTX-800 series to AUG for up to $45M in milestone payments; pipeline focused on immunology.","Q3 2023 net loss $5.2M ($0.11 diluted loss) vs net income $3.2M a year ago; revenue fell to $236K from $14.9M.","Cash and cash equivalents $10.2M at Sept 30, 2023; raised $46.2M net from equity financings in 9 months.","Advancing quisovalimab (anti-LIGHT mAb) toward planned ulcerative colitis trial; AVTX-008 BTLA agonist progressing to IND."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-038030","json":"https://secwatch.observer/filing/0001628280-23-038030.json","markdown":"https://secwatch.observer/filing/0001628280-23-038030.md","text":"https://secwatch.observer/filing/0001628280-23-038030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023038030/0001628280-23-038030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023038030/avtx-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:39:52.229338+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf5d01cdfe766f3f946e72f7d3f8488a32dbaeba","claim":"Avalo Therapeutics, Inc. reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"On November 9, 2023, Avalo Therapeutics, Inc. (the \"Company\") issued a press release announcing its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023038030/0001628280-23-038030-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}